Protalix BioTherapeutics (PLX) Long-Term Deferred Tax (2011 - 2026)

Protalix BioTherapeutics' Long-Term Deferred Tax history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 17.65% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $2.4 million, a 17.65% decrease from a year earlier, with the FY2025 full-year figure at $2.5 million, down 11.9% from the prior year.
• Long-Term Deferred Tax eased to $2.4 million in Q1 2026 per PLX's latest filing, from $2.5 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $3.3 million in Q2 2024 and bottomed at $2.4 million in Q1 2026.
• The 4-year median for Long-Term Deferred Tax is $2.9 million (2024), against an average of $2.9 million.
• Across the five-year window, Long-Term Deferred Tax grew 5.4% in 2024 and retreated 17.65% in 2026, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $3.1 million in 2023, then dropped by 7.63% to $2.9 million in 2024, then retreated by 11.9% to $2.5 million in 2025, then retreated by 2.82% to $2.4 million in 2026.
• Per Business Quant, the three latest PLX Long-Term Deferred Tax figures stand at $2.4 million (Q1 2026), $2.5 million (Q4 2025), and $2.7 million (Q3 2025).